Geode Capital Management LLC Cuts Position in MeiraGTx Holdings plc (NASDAQ:MGTX)

Geode Capital Management LLC lowered its position in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 1.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 490,239 shares of the company’s stock after selling 5,378 shares during the quarter. Geode Capital Management LLC owned about 0.76% of MeiraGTx worth $2,044,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MGTX. Rhumbline Advisers boosted its stake in shares of MeiraGTx by 10.8% in the second quarter. Rhumbline Advisers now owns 52,996 shares of the company’s stock valued at $223,000 after purchasing an additional 5,178 shares during the period. American Century Companies Inc. boosted its position in MeiraGTx by 42.4% in the 2nd quarter. American Century Companies Inc. now owns 40,008 shares of the company’s stock valued at $168,000 after buying an additional 11,907 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of MeiraGTx by 14.6% during the second quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock valued at $1,949,000 after acquiring an additional 58,854 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of MeiraGTx by 100.9% during the second quarter. Hsbc Holdings PLC now owns 23,954 shares of the company’s stock worth $102,000 after acquiring an additional 12,029 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of MeiraGTx during the second quarter worth about $123,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Stock Up 0.2 %

Shares of MGTX stock opened at $6.35 on Thursday. MeiraGTx Holdings plc has a 1 year low of $3.85 and a 1 year high of $7.37. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The business’s fifty day moving average is $6.27 and its 200-day moving average is $5.12. The stock has a market cap of $496.27 million, a PE ratio of -5.25 and a beta of 1.26.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on MGTX shares. Royal Bank of Canada lifted their price objective on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $36.00 price target on shares of MeiraGTx in a research note on Monday, November 18th.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.